Skip to main content
Erschienen in: Journal of Neuro-Oncology 3/2023

05.12.2023 | Research

Management strategies for intracranial progression in ALK-positive non-small cell lung cancer: a real-world cohort study

verfasst von: Chia-I Shen, Chi-Lu Chiang, Hsu-Ching Huang, Yen-Han Tseng, Yung-Hung Luo, Huai-Che Yang, Yuh-Min Chen

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

ALK-positive NSCLC patients exhibit a particularly high propensity for the development of brain metastases. Current guidelines suggest transit to next-line therapy (SysTx) or local radiotherapy (RadTx) including whole-brain radiotherapy and radiosurgery. However, the clinical impact of these two strategies remains unclear.

Methods

We conducted a retrospective analysis focusing on patients with stage IV ALK-positive NSCLC who underwent first-line ALK TKI treatment. Patients with intracranial progression may receive two different treatment strategies: SysTx and RadTx. Our objective was to investigate the outcomes associated with these two distinct treatment pathways.

Results

A total 20 patients of ALK-positive NSCLC who received first-line ALK TKI therapy and subsequently developed intracranial progression were enrolled. About 55% of patients had brain metastasis initially. Nine patients (45%) were treated with crizotinib at first. Patients treated with crizotinib demonstrated a significantly shorter intracranial PFS1 (crizotinib: 8.27 months vs. others: 27.0 months, p = 0.006). Following intracranial progression, approximately 60% of patients transitioned to the next line of systemic treatment (SysTx), while the remaining 40% opted for local cranial radiotherapy (RadTx). Intriguingly, our analysis revealed no statistically significant difference in intracranial progression-free survival (PFS2) between these two distinct treatment strategies. (SysTx: 20.87 months vs. RadTx: 28.23 months, p = 0.461).

Conclusion

The intracranial progression-free survival showed no difference between the two strategies suggesting that both local radiotherapy and systemic therapy may be valid options. Individualized strategy, molecular analysis, and multidisciplinary conferences may all play a pivotal role in decision-making.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ceddia S, Codacci-Pisanelli G (2021) Treatment of brain metastases in ALK-positive non-small cell lung cancer. Crit Rev Oncol Hematol 165:103400CrossRefPubMed Ceddia S, Codacci-Pisanelli G (2021) Treatment of brain metastases in ALK-positive non-small cell lung cancer. Crit Rev Oncol Hematol 165:103400CrossRefPubMed
2.
Zurück zum Zitat Peters S, Bexelius C, Munk V, Leighl N (2016) The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat Rev 45:139–162CrossRefPubMed Peters S, Bexelius C, Munk V, Leighl N (2016) The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat Rev 45:139–162CrossRefPubMed
3.
Zurück zum Zitat Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A et al (2023) NCCN guidelines insights: non-small cell lung cancer, version 2.2023. J Natl Compr Canc Netw 21(4):340–350CrossRefPubMed Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A et al (2023) NCCN guidelines insights: non-small cell lung cancer, version 2.2023. J Natl Compr Canc Netw 21(4):340–350CrossRefPubMed
4.
Zurück zum Zitat Nelson TA, Wang N (2023) Targeting lung cancer brain metastases: a narrative review of emerging insights for anaplastic Lymphoma kinase (ALK)-positive Disease. Transl Lung Cancer Res 12(2):379–392CrossRefPubMedPubMedCentral Nelson TA, Wang N (2023) Targeting lung cancer brain metastases: a narrative review of emerging insights for anaplastic Lymphoma kinase (ALK)-positive Disease. Transl Lung Cancer Res 12(2):379–392CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Buss EJ, Wang TJC (2018) Treatment of lung adenocarcinoma brain metastases: what is the role of radiotherapy in the age of precision medicine? Transl Lung Cancer Res 7(Suppl 4):S318–S20CrossRefPubMedPubMedCentral Buss EJ, Wang TJC (2018) Treatment of lung adenocarcinoma brain metastases: what is the role of radiotherapy in the age of precision medicine? Transl Lung Cancer Res 7(Suppl 4):S318–S20CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND et al (2016) Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol 34(2):123–129CrossRefPubMed Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND et al (2016) Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol 34(2):123–129CrossRefPubMed
7.
Zurück zum Zitat Dempke WC, Edvardsen K, Lu S, Reinmuth N, Reck M, Inoue A (2015) Brain metastases in NSCLC - are TKIs changing the treatment strategy? Anticancer Res 35(11):5797–5806PubMed Dempke WC, Edvardsen K, Lu S, Reinmuth N, Reck M, Inoue A (2015) Brain metastases in NSCLC - are TKIs changing the treatment strategy? Anticancer Res 35(11):5797–5806PubMed
8.
Zurück zum Zitat Liao HR, Chiang CL, Shen CI, Chen CJ, Yang HC, Wu HM et al (2022) EGFR mutant status and tyrosine-kinase inhibitors affect the GKRS outcomes for NSCLC brain metastases. J Neurooncol 159(3):675–684CrossRefPubMed Liao HR, Chiang CL, Shen CI, Chen CJ, Yang HC, Wu HM et al (2022) EGFR mutant status and tyrosine-kinase inhibitors affect the GKRS outcomes for NSCLC brain metastases. J Neurooncol 159(3):675–684CrossRefPubMed
9.
Zurück zum Zitat Matsunaga S, Shuto T (2021) Outcomes of gamma knife radiosurgery for brain metastases from anaplastic lymphoma kinase rearrangement-positive and EGFR mutation-positive non-small cell lung cancer. Cureus 13(12):e20398PubMedPubMedCentral Matsunaga S, Shuto T (2021) Outcomes of gamma knife radiosurgery for brain metastases from anaplastic lymphoma kinase rearrangement-positive and EGFR mutation-positive non-small cell lung cancer. Cureus 13(12):e20398PubMedPubMedCentral
10.
Zurück zum Zitat Weber B, Winterdahl M, Memon A, Sorensen BS, Keiding S, Sorensen L et al (2011) Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol 6(7):1287–1289CrossRefPubMed Weber B, Winterdahl M, Memon A, Sorensen BS, Keiding S, Sorensen L et al (2011) Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol 6(7):1287–1289CrossRefPubMed
11.
Zurück zum Zitat Togashi Y, Masago K, Masuda S, Mizuno T, Fukudo M, Ikemi Y et al (2012) Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 70(3):399–405CrossRefPubMed Togashi Y, Masago K, Masuda S, Mizuno T, Fukudo M, Ikemi Y et al (2012) Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 70(3):399–405CrossRefPubMed
12.
Zurück zum Zitat Chen YC, Lee CC, Chiang CL, Yang HC, Wu HM, Chen CJ et al Combined BBB-penetrant tyrosine kinase inhibitor and intracranial radiotherapy versus BBB-penetrant tyrosine kinase inhibitor alone for the treatment of EGFR-mutated non-small cell lung cancer patients with brain metastases. https://doi.org/10.21203/rs.3.rs-2960400/v1 Chen YC, Lee CC, Chiang CL, Yang HC, Wu HM, Chen CJ et al Combined BBB-penetrant tyrosine kinase inhibitor and intracranial radiotherapy versus BBB-penetrant tyrosine kinase inhibitor alone for the treatment of EGFR-mutated non-small cell lung cancer patients with brain metastases. https://​doi.​org/​10.​21203/​rs.​3.​rs-2960400/​v1
13.
Zurück zum Zitat Cho A, Untersteiner H, Hirschmann D, Shaltout A, Gobl P, Dorfer C et al (2020) Gamma knife radiosurgery for brain metastases in non-small cell lung cancer patients treated with immunotherapy or targeted therapy. Cancers (Basel). 12(12) Cho A, Untersteiner H, Hirschmann D, Shaltout A, Gobl P, Dorfer C et al (2020) Gamma knife radiosurgery for brain metastases in non-small cell lung cancer patients treated with immunotherapy or targeted therapy. Cancers (Basel). 12(12)
14.
Zurück zum Zitat Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D et al (2022) Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol 40(5):492–516CrossRefPubMed Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D et al (2022) Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol 40(5):492–516CrossRefPubMed
15.
Zurück zum Zitat Thomas NJ, Myall NJ, Sun F, Patil T, Mushtaq R, Yu C et al (2022) Brain metastases in EGFR- and ALK-Positive NSCLC: outcomes of central nervous system-penetrant tyrosine kinase inhibitors alone versus in combination with radiation. J Thorac Oncol 17(1):116–129CrossRefPubMed Thomas NJ, Myall NJ, Sun F, Patil T, Mushtaq R, Yu C et al (2022) Brain metastases in EGFR- and ALK-Positive NSCLC: outcomes of central nervous system-penetrant tyrosine kinase inhibitors alone versus in combination with radiation. J Thorac Oncol 17(1):116–129CrossRefPubMed
16.
Zurück zum Zitat Zhang Z, Guo H, Lu Y, Hao W, Han L (2019) Anaplastic lymphoma kinase inhibitors in non-small cell Lung cancer patients with brain metastases: a meta-analysis. J Thorac Dis 11(4):1397–1409CrossRefPubMedPubMedCentral Zhang Z, Guo H, Lu Y, Hao W, Han L (2019) Anaplastic lymphoma kinase inhibitors in non-small cell Lung cancer patients with brain metastases: a meta-analysis. J Thorac Dis 11(4):1397–1409CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W et al (2011) CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 29(15):e443–e445CrossRefPubMed Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W et al (2011) CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 29(15):e443–e445CrossRefPubMed
18.
Zurück zum Zitat Kim DW, Mehra R, Tan DSW, Felip E, Chow LQM, Camidge DR et al (2016) Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol 17(4):452–463CrossRefPubMedPubMedCentral Kim DW, Mehra R, Tan DSW, Felip E, Chow LQM, Camidge DR et al (2016) Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol 17(4):452–463CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW et al (2017) Alectinib versus crizotinib in untreated ALK-positive non-small-cell Lung cancer. N Engl J Med 377(9):829–838CrossRefPubMed Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW et al (2017) Alectinib versus crizotinib in untreated ALK-positive non-small-cell Lung cancer. N Engl J Med 377(9):829–838CrossRefPubMed
20.
Zurück zum Zitat Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS et al (2018) Brigatinib versus crizotinib in ALK-positive non-small-cell Lung cancer. N Engl J Med 379(21):2027–2039CrossRefPubMed Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS et al (2018) Brigatinib versus crizotinib in ALK-positive non-small-cell Lung cancer. N Engl J Med 379(21):2027–2039CrossRefPubMed
21.
Zurück zum Zitat Kodama T, Hasegawa M, Takanashi K, Sakurai Y, Kondoh O, Sakamoto H (2014) Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol 74(5):1023–1028CrossRefPubMed Kodama T, Hasegawa M, Takanashi K, Sakurai Y, Kondoh O, Sakamoto H (2014) Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol 74(5):1023–1028CrossRefPubMed
22.
Zurück zum Zitat Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G et al (2020) First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med 383(21):2018–2029CrossRefPubMed Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G et al (2020) First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med 383(21):2018–2029CrossRefPubMed
23.
Zurück zum Zitat Felip E, Shaw AT, Bearz A, Camidge DR, Solomon BJ, Bauman JR et al (2021) Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol 32(5):620–630CrossRefPubMed Felip E, Shaw AT, Bearz A, Camidge DR, Solomon BJ, Bauman JR et al (2021) Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol 32(5):620–630CrossRefPubMed
24.
Zurück zum Zitat Tan AC, Itchins M, Khasraw M (2020) Brain metastases in lung cancers with emerging targetable fusion drivers. Int J Mol Sci 21(4) Tan AC, Itchins M, Khasraw M (2020) Brain metastases in lung cancers with emerging targetable fusion drivers. Int J Mol Sci 21(4)
25.
Zurück zum Zitat Ou SH, Klempner SJ, Azada MC, Rausei-Mills V, Duma C (2015) Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: implications for Disease assessment and management. Lung Cancer 88(3):355–359CrossRefPubMed Ou SH, Klempner SJ, Azada MC, Rausei-Mills V, Duma C (2015) Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: implications for Disease assessment and management. Lung Cancer 88(3):355–359CrossRefPubMed
26.
Zurück zum Zitat Miller JA, Bennett EE, Xiao R, Kotecha R, Chao ST, Vogelbaum MA et al (2016) Association between radiation necrosis and tumor biology after stereotactic radiosurgery for brain metastasis. Int J Radiat Oncol Biol Phys 96(5):1060–1069CrossRefPubMed Miller JA, Bennett EE, Xiao R, Kotecha R, Chao ST, Vogelbaum MA et al (2016) Association between radiation necrosis and tumor biology after stereotactic radiosurgery for brain metastasis. Int J Radiat Oncol Biol Phys 96(5):1060–1069CrossRefPubMed
27.
Zurück zum Zitat Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A et al (2014) Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol 32(34):3810–3816CrossRefPubMedPubMedCentral Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A et al (2014) Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol 32(34):3810–3816CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Tsao MN, Xu W, Wong RK, Lloyd N, Laperriere N, Sahgal A et al (2018) Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev 1(1):CD003869PubMed Tsao MN, Xu W, Wong RK, Lloyd N, Laperriere N, Sahgal A et al (2018) Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev 1(1):CD003869PubMed
29.
Zurück zum Zitat Zhang I, Zaorsky NG, Palmer JD, Mehra R, Lu B (2015) Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol 16(13):e510–e521CrossRefPubMed Zhang I, Zaorsky NG, Palmer JD, Mehra R, Lu B (2015) Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol 16(13):e510–e521CrossRefPubMed
30.
Zurück zum Zitat Solomon BJ, Cappuzzo F, Felip E, Blackhall FH, Costa DB, Kim DW et al (2016) Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014. J Clin Oncol 34(24):2858–2865CrossRefPubMed Solomon BJ, Cappuzzo F, Felip E, Blackhall FH, Costa DB, Kim DW et al (2016) Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014. J Clin Oncol 34(24):2858–2865CrossRefPubMed
31.
Zurück zum Zitat Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ et al (2015) Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 33(17):1881–1888CrossRefPubMedPubMedCentral Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ et al (2015) Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 33(17):1881–1888CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat McCoach CE, Blakely CM, Banks KC, Levy B, Chue BM, Raymond VM et al (2018) Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK inhibitor resistance in non-small cell lung cancer. Clin Cancer Res 24(12):2758–2770CrossRefPubMedPubMedCentral McCoach CE, Blakely CM, Banks KC, Levy B, Chue BM, Raymond VM et al (2018) Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK inhibitor resistance in non-small cell lung cancer. Clin Cancer Res 24(12):2758–2770CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Sanchez-Herrero E, Serna-Blasco R, Ivanchuk V, Garcia-Campelo R, Domine Gomez M, Sanchez JM et al (2021) NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment. Mol Oncol 15(9):2363–2376CrossRefPubMedPubMedCentral Sanchez-Herrero E, Serna-Blasco R, Ivanchuk V, Garcia-Campelo R, Domine Gomez M, Sanchez JM et al (2021) NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment. Mol Oncol 15(9):2363–2376CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Dagogo-Jack I, Yoda S, Lennerz JK, Langenbucher A, Lin JJ, Rooney MM et al (2020) MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer. Clin Cancer Res 26(11):2535–2545CrossRefPubMedPubMedCentral Dagogo-Jack I, Yoda S, Lennerz JK, Langenbucher A, Lin JJ, Rooney MM et al (2020) MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer. Clin Cancer Res 26(11):2535–2545CrossRefPubMedPubMedCentral
Metadaten
Titel
Management strategies for intracranial progression in ALK-positive non-small cell lung cancer: a real-world cohort study
verfasst von
Chia-I Shen
Chi-Lu Chiang
Hsu-Ching Huang
Yen-Han Tseng
Yung-Hung Luo
Huai-Che Yang
Yuh-Min Chen
Publikationsdatum
05.12.2023
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 3/2023
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-023-04497-y

Weitere Artikel der Ausgabe 3/2023

Journal of Neuro-Oncology 3/2023 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.